Literature DB >> 21111934

Colchicine in clinical medicine. A guide for internists.

Giuseppe Cocco1, David C C Chu, Stefano Pandolfi.   

Abstract

Colchicine (COL) has been used in medicine for a long time. It is well recognized as a valid therapy in acute flares of gouty arthritis, familial Mediterranean fever (FMF), Behçet's disease, and recurring pericarditis with effusion. It has also been used to treat many inflammatory disorders prone to fibrosis, mostly with disappointing therapeutic results. The pharmacotherapeutic mechanism of action of COL in diverse diseases is not fully understood, thought it is known that the drug accumulates preferentially in neutrophils, and this effect is useful in FMF. COL shows a large interindividual bioavailability. Furthermore, interactions with drugs interfering with CYP3A4 dependent enzymes and P-glycoprotein occur and are clinically important. The dosage of COL must be reduced in patients with relevant hepatic and/or renal dysfunction. However, when appropriately used and contraindications have been excluded, oral COL is a safe treatment.
Copyright © 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21111934     DOI: 10.1016/j.ejim.2010.09.010

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  52 in total

Review 1.  Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis.

Authors:  Massimo Imazio; Yehuda Adler
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

Review 2.  Periodontal and other oral manifestations of immunodeficiency diseases.

Authors:  M E Peacock; R M Arce; C W Cutler
Journal:  Oral Dis       Date:  2016-10-10       Impact factor: 3.511

3.  The role of microtubules in neutrophil polarity and migration in live zebrafish.

Authors:  Sa Kan Yoo; Pui-Ying Lam; Mark R Eichelberg; Lauren Zasadil; William M Bement; Anna Huttenlocher
Journal:  J Cell Sci       Date:  2012-09-19       Impact factor: 5.285

Review 4.  Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors.

Authors:  Armen Yuri Gasparyan; Lilit Ayvazyan; Heather Blackmore; George D Kitas
Journal:  Rheumatol Int       Date:  2011-07-29       Impact factor: 2.631

Review 5.  An Update on Medical Treatment Options for Hidradenitis Suppurativa.

Authors:  I E Deckers; E P Prens
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

6.  Colchicine treatment reversibly blocks cytokinesis but not mitosis in Trypanosoma cruzi epimastigotes.

Authors:  Mariana Potenza; María Teresa Tellez-Iñón
Journal:  Parasitol Res       Date:  2014-11-20       Impact factor: 2.289

7.  Evidence of Clinically Meaningful Drug-Drug Interaction With Concomitant Use of Colchicine and Clarithromycin.

Authors:  Lorenzo Villa Zapata; Philip D Hansten; John R Horn; Richard D Boyce; Sheila Gephart; Vignesh Subbian; Andrew Romero; Daniel C Malone
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

Review 8.  Colchicine: an ancient drug with novel applications.

Authors:  B Dasgeb; D Kornreich; K McGuinn; L Okon; I Brownell; D L Sackett
Journal:  Br J Dermatol       Date:  2018-01-03       Impact factor: 9.302

9.  Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.

Authors:  Pornwalai Boonmuang; Surakit Nathisuwan; Nathorn Chaiyakunapruk; Wimon Suwankesawong; Pattreya Pokhagul; Nattawat Teerawattanapong; Pairin Supsongserm
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

Review 10.  Colchicine in addition to conventional therapy for pericarditis recurrence : An update meta-analysis.

Authors:  Y-L Li; S-B Qiao; J-Y Wang; Y-M Chen; J Luo; H-F Zhang
Journal:  Herz       Date:  2016-03-15       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.